$CURR -- News on wellness and beauty product line placement in major retail stores:
Sera Labs Inc. Products Now Available at Walmart, Bed Bath & Beyond, CVS and Target.com
April 14, 2022 (Globe Newswire)
Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond stores. Sera Labs also has garnered placement for its revolutionary oral thin film strip, Nutri-Strips(TM) on shelves at CVS and at Target.com. The Nutri-Strip technology is proprietary to Sera Labs and is the result of years of research and more than 25 patents by CURE Pharmaceutical.
Nancy Duitch, Sera Labs' CEO and CURE Pharmaceutical's Chief Strategic Officer, stated, "This is another fantastic branding and expansion achievement. Our goal is to differentiate our products by using advanced and proprietary technologies including unique high-tech delivery systems. Our formulations are derived from scientifically backed ingredients and marry problem-solving attributes with beautiful packaging that stands out on the shelf. In addition, the connection of our brand with one of the most respected and recognized actors in the world: Nicole Kidman - who serves as strategic partner and global brand ambassador - makes our company and brand a fierce competitor in the beauty and wellness industry."
Seratopical Revolution combines nature and science into one clean and nourishing line of beauty products. The line's P3P complex, developed by CURE Pharmaceutical, drives natural, clean, plant-based ingredients into the deeper layers of the skin by utilizing a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as a delivery system, which is incredibly drying to the skin, Seratopical Revolution's natural oil and surfactant delivery systems are highly efficacious and offer near immediate results.
Duitch continued, "We continue to build our successful brands via multiple marketing channels that create awareness and are return-on-investment driven. With shelf space and online access for both Seratopical Revolution and Nutri-Strips at the largest mass and drug retail stores in the country we have created a compelling opportunity to acquire new customers and drive sales at a faster pace."
About Sera Labs
Sera Labs is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD and clean plant-based products. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical(TM), and SeraLabs(TM), Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness. Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: Seratopicalrevolution.com, Seratopical.com, Seralabshealth.com and follow us on Instagram at @seratopical, as well as Twitter, and Facebook. Media contact: press@theseralabs.com.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is the pioneering developer of CUREform(TM), a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE's 25,000 square foot, FDA-registered, NSF cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"
, and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act" , which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE's judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Investor Contact:
investor@curepharma.com
Hanover International Inc.
Jim Hock
JH@hanoverintlinc.com
https://ml.globenewswire.com/media/ZTllMGM5Mz...ing-Co.png
Sera Labs Inc. Products Now Available at Walmart, Bed Bath & Beyond, CVS and Target.com
April 14, 2022 (Globe Newswire)
Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond stores. Sera Labs also has garnered placement for its revolutionary oral thin film strip, Nutri-Strips(TM) on shelves at CVS and at Target.com. The Nutri-Strip technology is proprietary to Sera Labs and is the result of years of research and more than 25 patents by CURE Pharmaceutical.
Nancy Duitch, Sera Labs' CEO and CURE Pharmaceutical's Chief Strategic Officer, stated, "This is another fantastic branding and expansion achievement. Our goal is to differentiate our products by using advanced and proprietary technologies including unique high-tech delivery systems. Our formulations are derived from scientifically backed ingredients and marry problem-solving attributes with beautiful packaging that stands out on the shelf. In addition, the connection of our brand with one of the most respected and recognized actors in the world: Nicole Kidman - who serves as strategic partner and global brand ambassador - makes our company and brand a fierce competitor in the beauty and wellness industry."
Seratopical Revolution combines nature and science into one clean and nourishing line of beauty products. The line's P3P complex, developed by CURE Pharmaceutical, drives natural, clean, plant-based ingredients into the deeper layers of the skin by utilizing a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as a delivery system, which is incredibly drying to the skin, Seratopical Revolution's natural oil and surfactant delivery systems are highly efficacious and offer near immediate results.
Duitch continued, "We continue to build our successful brands via multiple marketing channels that create awareness and are return-on-investment driven. With shelf space and online access for both Seratopical Revolution and Nutri-Strips at the largest mass and drug retail stores in the country we have created a compelling opportunity to acquire new customers and drive sales at a faster pace."
About Sera Labs
Sera Labs is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD and clean plant-based products. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical(TM), and SeraLabs(TM), Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness. Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: Seratopicalrevolution.com, Seratopical.com, Seralabshealth.com and follow us on Instagram at @seratopical, as well as Twitter, and Facebook. Media contact: press@theseralabs.com.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is the pioneering developer of CUREform(TM), a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE's 25,000 square foot, FDA-registered, NSF cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"
, and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act" , which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE's judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Investor Contact:
investor@curepharma.com
Hanover International Inc.
Jim Hock
JH@hanoverintlinc.com
https://ml.globenewswire.com/media/ZTllMGM5Mz...ing-Co.png
